Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 19/20 | 0.42 |
| ▸ | JAK1 | P23458 | 17/20 | 0.42 |
| ▸ | TYK2 | P29597 | 17/20 | 0.40 |
| ▸ | JAK3 | P52333 | 15/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17506905 | 0.90 | JAK2 (0.45) | JAK2JAK1TYK2JAK3L3MBTL1 | |
| SCHEMBL17500575 | 0.90 | JAK2 (0.45) | JAK2JAK1TYK2JAK3L3MBTL1 | |
| SCHEMBL15970381 | 0.89 | JAK2 (0.44) | JAK2JAK1TYK2JAK3L3MBTL1 | |
| SCHEMBL15970382 | 0.89 | JAK2 (0.44) | JAK2JAK1TYK2JAK3L3MBTL1 | |
| SCHEMBL15970199 | 0.87 | JAK2 (0.44) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL15970265 | 0.87 | JAK2 (0.44) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL15970202 | 0.87 | JAK2 (0.44) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL15970264 | 0.87 | JAK2 (0.44) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL17500909 | 0.87 | JAK2 (0.44) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL17500867 | 0.86 | JAK1 (0.46) | JAK2JAK1TYK2JAK3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3180344-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES USEFUL FOR INHIBITING JANUS KINASE | Pfizer Inc (US) | 2017-06-21 | — | — | EP | disclosed |
| WO-2016024185-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES USEFUL FOR INHIBITING JANUS KINASE | PFIZER INC. (US) | 2016-02-18 | — | — | WO | disclosed |